Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England
- PMID: 20356942
- PMCID: PMC3104821
- DOI: 10.1258/jms.2009.009094
Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England
Erratum in
- J Med Screen. 2010 Jun;17(2):106
Abstract
Objectives: To estimate the absolute numbers of breast cancer deaths prevented and the absolute numbers of tumours overdiagnosed in mammographic screening for breast cancer at ages 50-69 years.
Setting: The Swedish Two-County randomized trial of mammographic screening for breast cancer, and the UK Breast Screening Programme in England, ages 50-69 years.
Methods: We estimated the absolute numbers of deaths avoided and additional cases diagnosed in the study group (active study population) of the Swedish Two-County Trial, by comparison with the control group (passive study population). We estimated the same quantities for the mortality and incidence rates in England (1974-2004 and 1974-2003, respectively). We used Poisson regression for statistical inference.
Results: A substantial and significant reduction in breast cancer mortality was associated with screening in both the Two-County Trial (P < 0.001) and the screening programme in England (P < 0.001). The absolute benefits were estimated as 8.8 and 5.7 breast cancer deaths prevented per 1000 women screened for 20 years starting at age 50 from the Two-County Trial and screening programme in England, respectively. The corresponding estimated numbers of cases overdiagnosed per 1000 women screened for 20 years were, respectively, 4.3 and 2.3 per 1000.
Conclusions: The benefit of mammographic screening in terms of lives saved is greater in absolute terms than the harm in terms of overdiagnosis. Between 2 and 2.5 lives are saved for every overdiagnosed case.
Figures
Comment in
-
Absolute numbers of lives saved and overdiagnosis in breast cancer screening.J Med Screen. 2010;17(2):103; author reply 103. doi: 10.1258/jms.2010.010059. J Med Screen. 2010. PMID: 20660442 No abstract available.
-
Breast screening: why estimates differ by a factor of 20-25.J Med Screen. 2010;17(3):158-9; author reply 159-60. doi: 10.1258/jms.2010.010066. J Med Screen. 2010. PMID: 20956727 No abstract available.
Similar articles
-
Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.Health Technol Assess. 2020 Oct;24(55):1-24. doi: 10.3310/hta24550. Health Technol Assess. 2020. PMID: 33141657 Free PMC article. Clinical Trial.
-
Benefit-to-harm ratio of the Danish breast cancer screening programme.Int J Cancer. 2017 Aug 1;141(3):512-518. doi: 10.1002/ijc.30758. Epub 2017 May 10. Int J Cancer. 2017. PMID: 28470685 Free PMC article.
-
The benefits and harms of breast cancer screening: an independent review.Lancet. 2012 Nov 17;380(9855):1778-86. doi: 10.1016/S0140-6736(12)61611-0. Epub 2012 Oct 30. Lancet. 2012. PMID: 23117178 Review.
-
Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer.Breast Cancer Res. 2005;7(6):258-65. doi: 10.1186/bcr1354. Epub 2005 Nov 10. Breast Cancer Res. 2005. PMID: 16457701 Free PMC article.
-
Mammographic screening for breast cancer. Overdiagnosis: an insidious adverse effect of screening.Prescrire Int. 2015 Jul;24(162):186-9, 191. Prescrire Int. 2015. PMID: 26240891 Review.
Cited by
-
Survival outcomes of young-age female patients with early breast cancer: an international multicenter cohort study.ESMO Open. 2024 Oct 15;9(11):103732. doi: 10.1016/j.esmoop.2024.103732. Online ahead of print. ESMO Open. 2024. PMID: 39413678 Free PMC article.
-
Predicting Breast Cancer Risk Using Radiomics Features of Mammography Images.J Pers Med. 2023 Oct 25;13(11):1528. doi: 10.3390/jpm13111528. J Pers Med. 2023. PMID: 38003843 Free PMC article.
-
Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives.Cancers (Basel). 2022 Aug 30;14(17):4218. doi: 10.3390/cancers14174218. Cancers (Basel). 2022. PMID: 36077752 Free PMC article. Review.
-
Polygenic risk scores to stratify cancer screening should predict mortality not incidence.NPJ Precis Oncol. 2022 May 30;6(1):32. doi: 10.1038/s41698-022-00280-w. NPJ Precis Oncol. 2022. PMID: 35637246 Free PMC article. Review.
-
An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975-2017.J Invest Dermatol. 2022 Jul;142(7):1804-1811.e6. doi: 10.1016/j.jid.2021.12.003. Epub 2021 Dec 11. J Invest Dermatol. 2022. PMID: 34902365 Free PMC article.
References
-
- Tabar L, Vitak B, Yen MFA, Chen HHT, Smith RA, Duffy SW Number needed to screen-lives saved over 20 years of follow-up in mammographic screening. J Med Screen 2004;11:126–9 - PubMed
-
- Swedish Organised Service Screening Evaluation Group Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 2006;15:45–51 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
